Last reviewed · How we verify
NCT03092687
Procedures for Sample Acquisition and Distribution for The Human Brain Collection Core
trial in Schizophrenia in 192 participants. Terminated before completion.
29 August 2019
Quick facts
| Lead sponsor | National Institute of Mental Health (NIMH) |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 192 |
| Start date | 21 March 2017 |
| Primary completion | 29 August 2019 |
| Estimated completion | 29 August 2019 |
| Sites | 1 location across United States |
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
- Major Depression — all drugs for Major Depression →
- Bipolar Disorder — all drugs for Bipolar Disorder →
- PTSD — all drugs for PTSD →
Sponsor
National Institute of Mental Health (NIMH)
Who can join
Under 120, any sex, with Schizophrenia or Major Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: The Human Brain Collection Core (HBCC) collects brain and other tissues. They get these from deceased people who may or may not have had psychiatric disorders. The next of kin gives permission for researchers to get the tissues. Researchers want to collect medical details of people whose brains are donated. They also want to use the donated tissue to study brain chemistry and structure. This could lead to better treatments for mental illness. Objective: To create a collection of human brain tissue to learn about the causes and mechanisms of mental disorders. Eligibility: People willing to donate their deceased relative s brain tissue. The deceased person could not have had any of the following: Severe mental retardation Long-lasting seizure disorder Infections that affect the brain Decomposition Brain damage Being on a respirator for more than 12 hours Major sepsis Serious renal or hepatic disease Certain dementias and degenerative diseases Design: Medical Examiner s Offices will screen donors who have recently died. Some others will be screened by hospitals or funeral homes. Participants will be the next of kin. They will give consent for HBCC to obtain brain tissue from the deceased person. The tissue will be frozen for future research. Participants will have a 30-minute phone call. They will answer questions about the deceased person s medical and psychiatric conditions. They will answer questions about the person s use of medicines and drugs. Participants will be contacted by a social worker. They will be asked for permission to access the deceased person s medical records.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
CommonMind Consortium provides transcriptomic and epigenomic data for Schizophrenia and Bipolar Disorder.
Hoffman GE, Bendl J, Voloudakis G, Montgomery KS, et al · · 2019 · cited 200× · PMID 31551426 · DOI 10.1038/s41597-019-0183-6
Verify or expand the search:
- PubMed search for NCT03092687
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other National Institute of Mental Health (NIMH) trials
Trials by the same sponsor.
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT05652465 — Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive Disorder · Phase 2 · suspended
- NCT07027839 — Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B) · Phase 1 · recruiting
- NCT06920628 — PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 In · Phase 1 · recruiting
- NCT06874205 — Assessment of 11C-JMJ-129 for Imaging PDE4D in Brain and Whole Body of Healthy Volunteers · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03092687 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Mental Health (NIMH)
- Last refreshed: 6 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03092687.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing